Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Valvular Heart Disease Associated with Fenfluramine-Phentermine
NEJM 337:581-588, 629, 635, 63697., Connolly,H.M.,et al, 1997
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Brain Serotonin Neurotoxicity & Primary Pulmonary Hypertension from Fenfluramine & Dexfenfluramine
JAMA 278:666-672, McCann,U.D.,et al, 1997
Valve Disease Associated with Ergot Alkaloid Use:Echocardiographic and Pathologic Correlations
Ann Int Med 117:50-52, Redfield,M.M.,et al, 1992
Oral Anticoagulant Drugs
NEJM 324:1865-1875, Hirsh,J., 1991